Skip to main content
OpenTrials
Enrolling by Invitation

NCT Number: NCT06487962

Pilot RCT: FQHC Intervention for Uptake of CGM in Low-Income Adults With T1D

Low-income adults with type 1 diabetes (T1D), despite their disproportionate burden of acute complications (hypoglycemia and diabetes ketoacidosis) and related emergency department visits, hospitalizations, and death, remain largely disenfranchised from continuous glucose monitoring (CGM), an efficacious technology to mitigate these inequities. To increase CGM uptake in low-income, adults with T1D receiving diabetes management in federally qualified health centers (FQHCs), this pilot randomized control trial (RCT), will assess the feasibility of our study protocol, including our multi-level intervention informed by the Socio-Ecological Model.

Enrolling by Invitation

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Community Health Center, Inc., Middletown, Connecticut, United States

Loading trial locations.

About this study

Low-income adults with T1D experience a disproportionate burden of life-threatening, acute complications with high rates of related emergency department visits, hospitalizations, and death. Use of CGM may mitigate these inequities. Yet, low-income adults with T1D have exceptionally low levels of CGM use. This reflects social determinants of health (SODH), as framed by the multiple levels of the Socio-Ecological Model (SEM). The SEM's healthcare provider level is a main driver in Hispanic disenfranchisement from CGM. With a severe shortage of endocrinologists, primary care providers are increasingly managing T1D although many report inadequate confidence in titrating insulin and using CGM. With limited access to endocrinology, low-income, Hispanic adults with T1D thus often receive diabetes management in FQHCs with scant or no access to CGM. Hence, to foster equitable uptake of CGM in the most vulnerable adults with T1D, a 4-year, mixed-methods, feasibility study with a pilot randomized controlled trial (RCT) is underway to primarily assess the feasibility of the SEM-guided, 6-month intervention (targeting the individual, family/social networks, and healthcare provider levels). The SEM-guided intervention was refined by our Community Advisory Board. Refinements were informed by qualitative research exploring SDOH barriers to CGM uptake in low-income adults with T1D from the perspectives of four stakeholder groups.

The individual level of the intervention, guided by the Information-Motivation-Behavioral-Skills Model, fosters essential acquisition of information, motivation, and behavioral skills for CGM uptake through two principal approaches: (1) 4-week, personalized, CGM sessions with a RN/ certified diabetes care and education specialist (CDCES); and (2) subsequent virtual peer educator-led support groups, integrating CGM education, through study month six. The family/social networks level leverages social support to promote critical support in CGM uptake with a family member co-attending the 4-week sessions and participant engagement in peer-led support group sessions, respectively. The provider level of the intervention is designed to promote enhanced cultural competency in intervention delivery and provide clinical support for CGM informed by rigorous training in T1D management and CGM via Project ECHO (Extension for Community Healthcare Outcomes).

A total of 11 FQHC sites were randomized to deliver the intervention (n=6) or control (n=5) conditions with a total enrollment goal of 30 low-income adults with T1D (sites having roughly equivalent enrollment rates). The feasibility of the study protocol (e.g., recruitment and retention yields, data collection procedures, intervention implementation, and intervention acceptability, among others) will be routinely assessed. Significant intervention signals in terms of physiological (e.g., A1C and time within, above, and below range glucose range), psychosocial (e.g., quality of life and family support), and behavioral (CGM adherence) outcomes from baseline to 3- and 6-months post-baseline will be assessed. The long-term goal of this study is to inform a large, multi-site RCT, and with successful results, provide a model for CGM uptake in low-income adults with T1D for FQHCs nationally

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Low-income status
  • Documented diagnosis of T1D
  • 18 years of age or older
  • Federally Qualified Health Center (FQHC) primary care provider
  • English or Spanish-speaking And at intervention sites
  • Willingness to wear a CGM sensor
  • Adult family member or friend, who will give consent to participate in the study and co-attend the 4-week intervention sessions
  • Reported difficulty in using CGM if current or past use of CGM

Exclusion criteria

  • Pregnancy or planning to become pregnant
  • Lactation
  • Serious illness that may prevent study participation (e.g., severe depression)
  • Less than 6 months life expectancy
  • Alcohol abuse or dependence
  • Uncorrected hearing or vision impairment

Treatment and study plan

CGM Intervention

Device

The intervention has 4 components with CGM uptake and maintenance as a primary focus. (1) Participants will visit their primary care provider (PCP) at baseline and 3- and 6-months post-baseline (or more frequently as needed) for review of CGM data and insulin therapy adjustments as indicated. Intervention providers received rigorous training in T1D management and CGM via Project ECHO (Extension for Community Healthcare Outcomes). (2) After each PCP visit, the CDCES will follow-up with participants to ensure participant understanding of the education/instructions provided at the PCP visit. (3) Next, participants will receive 4-weekly sessions of culturally sensitive, intensive CGM education and training led by a CDCES with accompaniment of a supportive family member or friend. (4) Virtual group support sessions, led by a peer educator, will follow over 5 months. During this period, the peer-led sessions will take place every two weeks and then move to every three weeks.

SMBG Control Condition

Other

The SMBG control condition consists of 3 components delivered over 6 months. (1) Participants will visit their PCP at baseline and 3- and 6-months post-baseline (or more frequently as needed) for review of SMBG data and insulin therapy adjustments as indicated. Control providers received rigorous training in T1D management via Project ECHO. (2) Commencing after the first PCP visit, participants will have 4-weekly telehealth visits for knowledge and skills reinforcement for SMBG. (3) CDCES support phone calls will follow over 5 months. During this period, the support phone calls will take place every two weeks and then move to every three weeks.

Primary outcomes

  1. Number of days CGM worn

    Time frame: 3 months and 6 months

    The total number of days CGM worn. Data will be collected from Ambulatory Glucose Profile Reports.

  2. Percentage of time the CGM is active

    Time frame: 3 months and 6 months

    The percentage of time the CGM is active. Data will be collected from Ambulatory Glucose Profile Reports.

Secondary outcomes

  1. A1C

    Time frame: Baseline, 3 months, and 6 months

    Measure of glycemic control over the past 3 months

  2. CGM time in range (TIR)

    Time frame: 3 months and 6 months

    TIR is measured by CGM. Data will be collected from Ambulatory Glucose Profile Reports.

  3. CGM time below range (TBR)

    Time frame: 3 months and 6 months

    TBR is measured by CGM. Data will be collected from Ambulatory Glucose Profile Reports.

  4. CGM time above range (TAR)

    Time frame: 3 months and 6 months

    TAR is measured by CGM. Data will be collected from Ambulatory Glucose Profile Reports.

  5. Number of hypoglycemic-related emergency department (ED) visits over past 3 months

    Time frame: Baseline, 3 months, and 6 months

    1-item measure

  6. Number of hypoglycemic-related hospitalizations

    Time frame: Baseline, 3 months, and 6 months

    1-item measure

  7. Number of hyperglycemic-related ED visits

    Time frame: Baseline, 3 months, and 6 months

    1-item measure

  8. Number of hyperglycemic-related hospitalizations

    Time frame: Baseline, 3 months, and 6 months

    1-item measure

  9. Medical Outcomes Survey Short Form-36

    Time frame: Baseline, 3 months, and 6 months

    Quality of Life

  10. Multidimensional Scale of Perceived Social Support

    Time frame: Baseline, 3 months, and 6 months

    Social Support

  11. Interpersonal Processes of Care Survey: Short Form

    Time frame: Baseline, 3 months, and 6 months

    Disparities in Interpersonal Care (communication, decision-making, and interpersonal style)

Sponsors and collaborators

Lead sponsor

University of Connecticut

Other

Collaborators

  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Registry information

Important dates

Study start
2024
Primary completion
2026
Study completion
2026
First posted
Jul 5, 2024
Registry last updated
Aug 12, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.